Drug Trial Radar · NCT07006727
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Oct 16, 2025
Primary completion
Aug 29, 2031
Study completion Aug 29, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Conditions
- Small Cell Lung Carcinoma
- Large Cell Neuroendocrine Carcinoma of the Lung
- Neuroendocrine Prostate Cancer
- Gastroenteropancreatic Neuroendocrine Carcinoma
- Non-prostate Extrapulmonary Neuroendocrine Carcinoma
- Cervical Neuroendocrine Carcinoma
- Thymic Neuroendocrine Carcinoma
- Genitourinary Neuroendocrine Carcinoma
- Unknown Primary Neuroendocrine Carcinomas
- Merkel Cell Carcinoma
- Medullary Thyroid Carcinoma
Interventions
225Ac-ETN029Drug
Radioligand therapy
111In-ETN029Drug
Radioligand imaging agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with dose limiting toxicities of 225Ac-ETN029Time frame: From the start of study treatment until 6 weeks after
- Incidence and severity of adverse events and serious adverse events of 225Ac-ETN029Time frame: From start of study treatment until completion of the 36 month follow up, assessed up to approximately 42 months
- Dose modifications for 225Ac-ETN029Time frame: From the start of study treatment until last dose of study treatment, assessed as approximately 24 weeks
- Dose intensity for 225Ac-ETN029Time frame: From start of study treatment until last dose of study treatment, assessed as approximately 24 weeks
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
University Of Iowa
Iowa City, Iowa · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Corewell Health William Beaum Hosp
Royal Oak, Michigan · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Chuo Ku, Tokyo, Japan · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.